BeiGene
BGNE
#881
Rank
ยฃ16.89 B
Marketcap
ยฃ153.91
Share price
1.71%
Change (1 day)
-1.81%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (BGNE) - Total assets

Total assets on the balance sheet as of June 2024 : ยฃ4.35 B

According to BeiGene 's latest financial reports the company's total assets are ยฃ4.35 B. A companyโ€™s total assets is the sum of all current and non-current assets, such as inventories, cash and cash equivalents, properties and equipment.

BeiGene - Total assets on balance sheet (from 2014 to 2024)

Total assets by year

Year Total assets Change
2023-12-31ยฃ4.55 B-13.58%
2022-12-31ยฃ5.27 B-16.39%
2021-12-31ยฃ6.30 B53.73%
2020-12-31ยฃ4.10 B237.68%
2019-12-31ยฃ1.21 B-31.09%
2018-12-31ยฃ1.76 B127.71%
2017-12-31ยฃ0.77 B135.43%
2016-12-31ยฃ0.32 B317.84%
2015-12-31ยฃ78.71 M128.51%
2014-12-31ยฃ34.44 M382.16%
2013-12-31ยฃ7.14 M

Total Assets for similar companies or competitors

Company Total assets differencediff. Country
ยฃ13.84 M-99.68%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ1.50 B-65.34%๐Ÿ‡บ๐Ÿ‡ธ USA